ContextTamoxifen is approved for the reduction of breast cancer risk, and raloxifene has
demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis.
ObjectiveTo compare the relative effects and safety of raloxifene and tamoxifen on the risk of
developing invasive breast cancer and other disease outcomes. Design, Setting, and
PatientsThe National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and
Raloxifene trial, a prospective, double-blind, randomized clinical trial conducted beginning …